Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1996 1
1999 1
2000 3
2001 2
2002 2
2003 5
2004 8
2005 10
2006 18
2007 15
2008 15
2009 14
2010 9
2011 20
2012 11
2013 11
2014 7
2015 20
2016 28
2017 21
2018 22
2019 15
2020 32
2021 34
2022 30
2023 20
2024 16
2025 16

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

360 results

Results by year

Filters applied: . Clear all
Page 1
Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study.
Burtness B, Harrington KJ, Greil R, Soulières D, Tahara M, de Castro G Jr, Psyrri A, Basté N, Neupane P, Bratland Å, Fuereder T, Hughes BGM, Mesía R, Ngamphaiboon N, Rordorf T, Wan Ishak WZ, Hong RL, González Mendoza R, Roy A, Zhang Y, Gumuscu B, Cheng JD, Jin F, Rischin D; KEYNOTE-048 Investigators. Burtness B, et al. Lancet. 2019 Nov 23;394(10212):1915-1928. doi: 10.1016/S0140-6736(19)32591-7. Epub 2019 Nov 1. Lancet. 2019. PMID: 31679945 Clinical Trial.
Resveratrol for cancer therapy: Challenges and future perspectives.
Ren B, Kwah MX, Liu C, Ma Z, Shanmugam MK, Ding L, Xiang X, Ho PC, Wang L, Ong PS, Goh BC. Ren B, et al. Among authors: goh bc. Cancer Lett. 2021 Sep 1;515:63-72. doi: 10.1016/j.canlet.2021.05.001. Epub 2021 May 28. Cancer Lett. 2021. PMID: 34052324 Free article. Review.
A glycolytic metabolite bypasses "two-hit" tumor suppression by BRCA2.
Kong LR, Gupta K, Wu AJ, Perera D, Ivanyi-Nagy R, Ahmed SM, Tan TZ, Tan SL, Fuddin A, Sundaramoorthy E, Goh GS, Wong RTX, Costa ASH, Oddy C, Wong H, Patro CPK, Kho YS, Huang XZ, Choo J, Shehata M, Lee SC, Goh BC, Frezza C, Pitt JJ, Venkitaraman AR. Kong LR, et al. Among authors: goh bc. Cell. 2024 Apr 25;187(9):2269-2287.e16. doi: 10.1016/j.cell.2024.03.006. Epub 2024 Apr 11. Cell. 2024. PMID: 38608703 Free article.
Hyperphosphorylation of BCL-2 family proteins underlies functional resistance to venetoclax in lymphoid malignancies.
Chong SJF, Zhu F, Dashevsky O, Mizuno R, Lai JX, Hackett L, Ryan CE, Collins MC, Iorgulescu JB, Guièze R, Penailillo J, Carrasco R, Hwang YC, Muñoz DP, Bouhaddou M, Lim YC, Wu CJ, Allan JN, Furman RR, Goh BC, Pervaiz S, Coppé JP, Mitsiades CS, Davids MS. Chong SJF, et al. Among authors: goh bc. J Clin Invest. 2023 Nov 15;133(22):e170169. doi: 10.1172/JCI170169. J Clin Invest. 2023. PMID: 37751299 Free PMC article.
Exosome autoantibody biomarkers for detection of lung cancer.
Thuya WL, Peyper JM, Myen TT, Anuar ND, Anwar A, Gudimella R, Rutt NH, Rosli NSM, Badri NH, Rahman TNA, Nurashirin R, Sethi G, Tam JKC, Wong AL, Soo R, Blackburn JM, Wang L, Goh BC. Thuya WL, et al. Among authors: goh bc. Mil Med Res. 2024 Nov 18;11(1):72. doi: 10.1186/s40779-024-00575-y. Mil Med Res. 2024. PMID: 39558443 Free PMC article. No abstract available.
Pembrolizumab with or without bevacizumab in platinum-resistant recurrent or metastatic nasopharyngeal carcinoma: a randomised, open-label, phase 2 trial.
Chong WQ, Low JL, Tay JK, Le TBU, Goh GS, Sooi K, Teo HL, Cheo SW, Wong RT, Samol J, Lim MY, Li H, Shirgaonkar N, Chia S, Wang L, Gopinathan A, Eu DK, Tsang RK, Loh KS, Toh HC, Syn N, Kong LR, Dasgupta R, Tai BC, Lim YC, Goh BC. Chong WQ, et al. Among authors: goh bc. Lancet Oncol. 2025 Feb;26(2):175-186. doi: 10.1016/S1470-2045(24)00677-6. Epub 2025 Jan 15. Lancet Oncol. 2025. PMID: 39826567 Clinical Trial.
360 results